We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Ovoca Bio Plc | OVB | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.05 | -6.06% | 0.775 | 12:06:43 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.825 | 0.775 | 0.825 | 0.775 | 0.825 |
| Industry Sector |
|---|
| MINING |
| Top Posts |
|---|
Posted at 23/2/2022 18:51 by texas ranger This scammer has been bankrupt after many failed P&DLook at the size he trades £1000 and held for nearly 3 years. Good luck following a giro investor, who most probably lives on a council estate, smoke ciggies with taxpayers more. When I am telling this filth, is the most hated criminal scammer on ADVFN it's true. dave454523 Feb '22 - 09:07 - 458 of 470 I knew this would happen. I tried like everybody else to sell at 25p bid but it was almost impossible. I sold 5000 at 25p and bought them back 19.75p |
Posted at 23/2/2022 18:34 by letmepass Dave4545 has lost alot of investors lots of money with his pumping of many shares. Beware of the scammer. This company will need funds. This is Russia. Mms will slowly drop this until next news. |
Posted at 07/2/2022 09:44 by hedgehog 100 Here is OVB's share price chart since the start of last year: a rise of 38.46%, from 9.75p to 13.5p.Many investors over the last year would have appreciated that sort of 'boringness'! That said, I would agree that the real excitement is still to come! |
Posted at 12/11/2021 09:13 by dave4545 Imagine if it went to US trials and US investors used to pay hundreds of millions for just about everything looked at this and thought hold on"it's worth £10 mil and has £8 mil cash" and this could be sold all over the world. This current price is assuming 100% failure in reality |
Posted at 04/8/2021 18:05 by hedgehog 100 Last summer was a period of excellent OVB share price performance, starting with its final results, as investors anticipated Russian marketing approval, and the same should apply this time too.Ultimately approval last year was temporarily knocked back, but only for minor procedural 'box-ticking' stuff. Crucially, there were no concerns raised about the drug's effectiveness or safety, which are the two key criteria: 02/10/2020 07:00 UK Regulatory (RNS & others) Ovoca Bio PLC Update re Russian Marketing Authorisation " ... Ovoca has been informed that the Minzdrav has not granted the MA to BP-101 following the identification of certain issues relating to the chemistry, manufacturing and controls (CMC) and labelling sections of the MA submission dossier. The Company notes that no issues were highlighted by the Minzdrav regarding the safety or efficacy of BP-101 in the acquired generalized form of HSDD, which has been established by clinical data from two Phase 1 studies, a Phase 2a study and the pivotal Phase 3 study completed in 2019, all as conducted in the Russian Federation. ..." So approval this time round looks like a formality, and it could be as early as October. |
Posted at 04/8/2021 17:25 by hedgehog 100 Jim,I think there's a fairly narrow window of opportunity to buy in at about the current levels. Russian marketing approval is expected in October-December, and savvy investors will likely be buying in ahead of that in anticipation ... with some leeway, to 'beat the rush'. And with an illiquid share like this, it can take quite some time - perhaps even weeks - to accumulate a decent stake, as you wait for sales to become available. |
Posted at 28/7/2021 17:32 by hedgehog 100 "Subject to international Covid-19 restrictions, the Ovoca Bio management team and scientists attend key industry events and conferences to meet with potential partners and investors.To arrange a meeting with the team at any of the conferences listed below, please contact info@ovocabio.com DATE EVENT LOCATION NOTES June 10-11 & 14-18, 2021 BIO Digital Web-based North America Partnering Conference October 2021 BIO Europe Web-based European Partnering Conference" Interesting to see that OVB is attending web-based partnering conferences for both Europe and North America. This ties in with the company's stated global expansion plan: 24/06/2021 07:00 UK Regulatory (RNS & others) Ovoca Bio PLC Annual Report and Notice of AGM LSE:OVB Ovoca Bio Plc " ... Ovoca Bio is seeking to develop the drug for major global markets - in particular the United States and Europe, as well as obtain marketing approval in the Russian Federation. ..." |
Posted at 14/7/2021 19:50 by hedgehog 100 Is there another active biotech on the London stock market with a market cap. this low? (£8.36M. at 10.25p)Not that I'm aware of. You might think therefore that one or all of the following would apply: • Lack of cash, and fundraising imminent. • Very early stage, and no trials passed. • Tiny niche market. Whereas in fact, the company is cash-rich, has passed phase-III trials in Russia, and is targeting a massive market ... Would the investor interest be different if the company had developed a nasal spray to give men orgasms, rather than women?! |
Posted at 26/6/2021 20:48 by hedgehog 100 24/06/2021 07:00 UKREG Ovoca Bio PLC Annual Report and Notice of AGMWell, OVB's finals are out, as well as a new presentation on the company's website, and it all makes for very arousing reading! The news that OVB's drug can also help with female orgasms is great news, and it underlines how OVB could have a 'licence to print money' here ... or should I say a 'licence to make women runny'!! Last summer was a period of excellent OVB share price performance, starting with its final results, as investors anticipated Russian marketing approval, and the same should apply this time too. Ultimately approval last year was temporarily knocked back, but only for minor procedural 'box-ticking' stuff. Crucially, there were no concerns raised about the drug's effectiveness or safety, which are the two key criteria: 02/10/2020 07:00 UK Regulatory (RNS & others) Ovoca Bio PLC Update re Russian Marketing Authorisation " ... Ovoca has been informed that the Minzdrav has not granted the MA to BP-101 following the identification of certain issues relating to the chemistry, manufacturing and controls (CMC) and labelling sections of the MA submission dossier. The Company notes that no issues were highlighted by the Minzdrav regarding the safety or efficacy of BP-101 in the acquired generalized form of HSDD, which has been established by clinical data from two Phase 1 studies, a Phase 2a study and the pivotal Phase 3 study completed in 2019, all as conducted in the Russian Federation. ..." So approval this time round looks like a formality, and it could be as early as October. That should give an immediate big boost to the s.p., and should be followed by news on this: "Discussions are progressing with a leading local candidate that can both manufacture and distribute BP-101." Sales should then commence in Russia, the world's largest country, providing great cashflow to complement OVB's already excellent balance sheet. And we also have the results of the Australia and New Zealand trials to look forward to, probably by the end of the year, a major step on the road to opening up other markets, including Europe and the US. It's quite incredible that you can buy such a well-funded and proven biotech, with such massive potential, for a sub £10M. market cap. A market cap. of £100s of millions looks very possible longer-term if the company delivers upon its potential. |
Posted at 10/2/2020 13:22 by tommyl1 Someone on one of the other boards suggests that the directors are milking the poly shares to pay themselves big salaries until it runs dry.My question is would the large investors such as Chase continue to hold shares if this is what was happening or do they have their hand in the till some way also? If so the money wont last very long. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
